Changing Fortunes in the Valsartan MDL?

Litigation attorney Eric Alexander authored a Drug & Device Law article analyzing new developments in the Valsartan multidistrict litigation (MDL). In the article, Mr. Alexander contrasts the Valsartan MDL's previous trajectory — largely shaped by plaintiff-friendly rulings — with a recent significant decision from the newly assigned judge in the U.S. District Court for the District of New Jersey. He explores how the court scrutinized the admissibility of plaintiffs' expert economic opinions supporting claims for full refunds on allegedly contaminated drugs and emphasized the need for scientific evidence linking contamination to actual harm. The article highlights the importance of reliable expert testimony and the evolving legal standards governing product liability claims in pharmaceutical MDLs.

READ: Changing Fortunes in the Valsartan MDL?